Nov 6, 2026Weekly roundupUpdated

AstraZeneca completes AZD4144-itraconazole PK study; posts five trial records this week

AstraZeneca's week spanned a Phase 3 lymphoma trial, a completed drug-interaction study, an obesity PK trial, a Cambridge-led imaging study, and a closed Brazil observational study.

AstraZeneca posted updates across five trial records in the week ending November 3, 2026.

Phase 3, large B-cell lymphoma: AstraZeneca registered the "Soundtrack D3" study testing surovatamig added to R-CHOP chemotherapy in patients 18 to under 80 with previously untreated large B-cell lymphoma and an IPI score of 2 to 5. The study evaluates surovatamig combined with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone in this population.¹ The trial is not yet recruiting, with planned enrollment of 1,200 participants and a primary outcome of progression-free survival assessed by Blinded Independent Central Review.¹
Phase 1, drug interaction: AstraZeneca completed a study of AZD4144 given alone and with itraconazole in healthy volunteers. The purpose was to assess the pharmacokinetics of AZD4144 when administered alone and in combination with itraconazole in healthy participants.² The trial enrolled 32 participants² at a single UK site, with primary completion on October 22, 2026.
Phase 1, overweight/obesity: AstraZeneca registered a single-dose trial comparing different subcutaneous formulations of AZD9550 and AZD6234. The study aims to compare blood levels and side effects after administration of different formulations of these two test medicines in participants living with overweight or obesity.³ It is not yet recruiting and plans to enroll 60 healthy men and women aged 18-55 years at one site in Nottingham, United Kingdom.³
Imaging study, lupus: A University of Cambridge-sponsored study with AstraZeneca as a collaborator is recruiting patients to examine anifrolumab's effect on arterial inflammation in systemic lupus erythematosus. The study investigates the effects of the interferon-targeting drug anifrolumab on arterial inflammation, measured by PET/MRI imaging before and after treatment.⁴ Planned enrollment is 15 participants.⁴
Observational, hyperkalaemia in Brazil: AstraZeneca's retrospective HOPE study is listed as completed. The study drew on anonymised data from the Hi Technologies Ltda. database covering patients from private cardiology, nephrology, and dialysis clinics in Brazil.⁵ Enrollment reached 6,434 participants.⁵

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.

Sources

A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5 ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 4, 2026. Story written by readthrough.
Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 5, 2026. Story written by readthrough.
A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 4, 2026. Story written by readthrough.
Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 5, 2026. Story written by readthrough.
Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 4, 2026. Story written by readthrough.
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 6, 2026. Story written by readthrough.
Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC Patients ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 6, 2026. Story written by readthrough.
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 6, 2026. Story written by readthrough.
Breast Cancer Real-World Insights and Decision Guidance Evaluation in Hong Kong ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 6, 2026. Story written by readthrough.
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 6, 2026. Story written by readthrough.
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 6, 2026. Story written by readthrough.
A Study to Screen for Lung Cancer in High-risk Individuals Who Have Never Smoked Using Low-dose Computed Tomography (LDCT). ClinicalTrials.gov
Source: ClinicalTrials.gov, National Library of Medicine. Data processed Nov 6, 2026. Story written by readthrough.

About

anifrolumab-fnia AstraZeneca AZD4144 AZD9550 durvalumab itraconazole lenbelintide ravulizumab surovatamig vincristine cyclophosphamide docetaxel doxorubicin leucovorin oxaliplatin prednisone rituximab tremelimumab-actl